Works matching IS 03407004 AND DT 2020 AND VI 69 AND IP 1
Results: 16
CD200 mimetic aptamer PEG-M49 markedly increases the therapeutic effects of pegylated liposomal doxorubicin in a mouse model of metastatic breast carcinoma: an effect independent of CD200 receptor 1.
- Published in:
- Cancer Immunology, Immunotherapy, 2020, v. 69, n. 1, p. 103, doi. 10.1007/s00262-019-02444-3
- By:
- Publication type:
- Article
Chemotherapy markedly reduces B cells but not T cells and NK cells in patients with cancer.
- Published in:
- Cancer Immunology, Immunotherapy, 2020, v. 69, n. 1, p. 147, doi. 10.1007/s00262-019-02449-y
- By:
- Publication type:
- Article
Personalized neoantigen-pulsed dendritic cell vaccines show superior immunogenicity to neoantigen-adjuvant vaccines in mouse tumor models.
- Published in:
- Cancer Immunology, Immunotherapy, 2020, v. 69, n. 1, p. 135, doi. 10.1007/s00262-019-02448-z
- By:
- Publication type:
- Article
Tumor mutation burden and immunological, genomic, and clinicopathological factors as biomarkers for checkpoint inhibitor treatment of patients with non-small-cell lung cancer.
- Published in:
- Cancer Immunology, Immunotherapy, 2020, v. 69, n. 1, p. 127, doi. 10.1007/s00262-019-02446-1
- By:
- Publication type:
- Article
IL-17A promotes fatty acid uptake through the IL-17A/IL-17RA/p-STAT3/FABP4 axis to fuel ovarian cancer growth in an adipocyte-rich microenvironment.
- Published in:
- Cancer Immunology, Immunotherapy, 2020, v. 69, n. 1, p. 115, doi. 10.1007/s00262-019-02445-2
- By:
- Publication type:
- Article
Mechanisms of immune evasion in bladder cancer.
- Published in:
- Cancer Immunology, Immunotherapy, 2020, v. 69, n. 1, p. 3, doi. 10.1007/s00262-019-02443-4
- By:
- Publication type:
- Article
Tailoring early-phase clinical trial design to address multiple research objectives.
- Published in:
- Cancer Immunology, Immunotherapy, 2020, v. 69, n. 1, p. 95, doi. 10.1007/s00262-019-02442-5
- By:
- Publication type:
- Article
GCN2 is essential for CD8<sup>+</sup> T cell survival and function in murine models of malignant glioma.
- Published in:
- Cancer Immunology, Immunotherapy, 2020, v. 69, n. 1, p. 81, doi. 10.1007/s00262-019-02441-6
- By:
- Publication type:
- Article
Interleukin-38 in colorectal cancer: a potential role in precision medicine.
- Published in:
- Cancer Immunology, Immunotherapy, 2020, v. 69, n. 1, p. 69, doi. 10.1007/s00262-019-02440-7
- By:
- Publication type:
- Article
A highly efficient modality to block the degradation of tryptophan for cancer immunotherapy: locked nucleic acid-modified antisense oligonucleotides to inhibit human indoleamine 2,3-dioxygenase 1/tryptophan 2,3-dioxygenase expression.
- Published in:
- Cancer Immunology, Immunotherapy, 2020, v. 69, n. 1, p. 57, doi. 10.1007/s00262-019-02438-1
- By:
- Publication type:
- Article
Proteolytic processing of PD-L1 by ADAM proteases in breast cancer cells.
- Published in:
- Cancer Immunology, Immunotherapy, 2020, v. 69, n. 1, p. 43, doi. 10.1007/s00262-019-02437-2
- By:
- Publication type:
- Article
Solid pavestones are needed to pave a solid way to success.
- Published in:
- 2020
- By:
- Publication type:
- Editorial
VISTA expression is associated with a favorable prognosis in patients with high-grade serous ovarian cancer.
- Published in:
- Cancer Immunology, Immunotherapy, 2020, v. 69, n. 1, p. 33, doi. 10.1007/s00262-019-02434-5
- By:
- Publication type:
- Article
Characterization of tumor-infiltrating immune cells in relation to microbiota in colorectal cancers.
- Published in:
- Cancer Immunology, Immunotherapy, 2020, v. 69, n. 1, p. 23, doi. 10.1007/s00262-019-02433-6
- By:
- Publication type:
- Article
Association of immune-related pneumonitis with the presence of preexisting interstitial lung disease in patients with non-small lung cancer receiving anti-programmed cell death 1 antibody.
- Published in:
- Cancer Immunology, Immunotherapy, 2020, v. 69, n. 1, p. 15, doi. 10.1007/s00262-019-02431-8
- By:
- Publication type:
- Article
Correction to: Preclinical assessment of transiently TCR redirected T cells for solid tumour immunotherapy.
- Published in:
- 2020
- By:
- Publication type:
- Correction Notice